Cycliramine is a substituted piperidine derivative discovered by Schering Corp. The drug is claimed to have antihistamine, antispasmodic, antiacetylcholine and analgesic activity.

Metaterol is a beta-adrenoceptor agonist. It exerts sympathomimetic and broncholytic properties.

Cinaproxen is naproxen derivative developed by Nicox S.A. for oxidative stress prevention and treatment.

Diacetamate (Acetaminophen Acetate, Acetaminophen Impurity, diacetyl-p-aminophenol) is a acetaminophen synthetic impurity. Acetaminophen-aspirin mixtures have lower stability due to acetylation of the former by the latter, producing diacetyl-p-aminophenol.

Dexproxibutene is an experimental agent structurally related to propoxyphene. It is an analgesic agent. Dexproxibutene is not very effective in rheumatoid arthritis pain relief. It is intermediate in effectiveness between distalgesic, codis, aspirin and placebo.

Esorubicin (4'-deoxydoxorubicin, NSC 267469) is a synthetic derivative of the anthracycline antineoplastic antibiotic doxorubicin with potential antineoplastic activity. Esorubicin intercalates into DNA and inhibits topoisomerase II, thereby inhibiting DNA replication and ultimately, interfering with RNA and protein synthesis. This agent exhibits less cardiotoxicity than the parent antibiotic doxorubicin, but may cause more severe myelosupression compared to other compounds within the anthracycline class. Esorubicin was being clinically tested for the treatment of solid tumors as well as lymphomas an leukemias. Esorubicin development has been discontinued.

Betamethadol or β-methadol is an opioid analgesic under international control according to the UN Single Convention 1961. Betamethadol is an isomer of the racemic mixture of dimepheptanol.

Detorubicin is a semi-synthetic derivative of the anthracycline antineoplastic antibiotic. It intercalates into DNA and interacts with topoisomerase II, thereby inhibiting DNA replication and repair and RNA and protein synthesis. This agent also produces toxic free-radical intermediates and interacts with cell membrane lipids causing lipid peroxidation. Detorubicin is less toxic than daunorubicin. Although it showed some clinical activity, the drug appeared to have no particular advantage over doxorubicin except for demonstrated activity against malignant melanoma. Unfortunately, detorubicin clearly has cardiac toxicity – in clinical trial, one patient developed congestive heart failure and other patients revealed endomyocardial biopsy evidence of cardiac toxicity.